Nathan L. Board

Nov 28, 2024 | cell.com | Milica Moskovljevic |Filippo Dragoni |Nathan L. Board |Fengting Wu |Jun S. Lai |Hao Zhang | +10 more

Keywords HIV-1 persistence HIV-1 latent reservoir latency reversal antigenic stimulation dendritic cells CD4+ T cells cytomegalovirus Introduction Antiretroviral therapy (ART) effectively blocks viral replication, but HIV-1 persists in a small pool of latently infected resting CD4+ T cells harboring inducible, replication-competent proviruses.1,2,3 This reservoir was originally characterized with a quantitative viral outgrowth assay (QVOA) in which resting CD4+ T cells are stimulated with...

Mar 1, 2024 | biorxiv.org | Filippo Dragoni |Nathan L. Board |Fengting Wu |Milica Moskovjlevic

AbstractDespite antiretroviral therapy (ART), HIV-1 persists in latently-infected CD4+ T cells, preventing cure. Antigens drive the proliferation of infected cells, precluding latent reservoir decay. However, the relationship between antigen recognition and HIV-1 gene expression is poorly understood since most studies of latency reversal use agents that induce non-specific global T cell activation.

Feb 29, 2024 | cell.com | Wei Bu |Ashish Kumar |Nathan L. Board

• None Isolated mAbs to EBV gp42, which is required for the fusion of the virus to B cells• None gp42 mAbs A10 and 4C12 use different mechanisms to inhibit EBV fusion to B cells• None Two distinct sites were identified on gp42 for receptor binding and for fusion to B cells• None gp42 mAb A10 prevented viremia and EBV lymphoma in humanized mice challenged with virusEpstein-Barr virus (EBV) causes infectious mononucleosis and is associated with B cell lymphomas.

Jan 26, 2024 | nature.com | Nathan L. Board |Milica Moskovljevic |Francesco Simonetti |Janet D. Siliciano |Luis Montaner |Sung Soo Mun

AbstractThe persistence of CD4+ T cells carrying latent human immunodeficiency virus-1 (HIV-1) proviruses is the main barrier to a cure. New therapeutics to enhance HIV-1-specific immune responses and clear infected cells will probably be necessary to achieve reduction of the latent reservoir. In the present study, we report two single-chain diabodies (scDbs) that target the HIV-1 envelope protein (Env) and the human type III Fcγ receptor (CD16).